266 related articles for article (PubMed ID: 37249834)
1. Cardiotoxicities of Non-Chemotherapeutic Metastatic Breast Cancer Treatments.
Soltani M; Sokoloff LJ; Fradley MG
Curr Oncol Rep; 2023 Aug; 25(8):923-935. PubMed ID: 37249834
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular Disease Amongst Women Treated for Breast Cancer: Traditional Cytotoxic Chemotherapy, Targeted Therapy, and Radiation Therapy.
Chen DH; Tyebally S; Malloupas M; Roylance R; Spurrell E; Raja F; Ghosh AK
Curr Cardiol Rep; 2021 Jan; 23(3):16. PubMed ID: 33501515
[TBL] [Abstract][Full Text] [Related]
3. New Insights on the Toxicity on Heart and Vessels of Breast Cancer Therapies.
Lanza O; Ferrera A; Reale S; Solfanelli G; Petrungaro M; Tini Melato G; Volpe M; Battistoni A
Med Sci (Basel); 2022 May; 10(2):. PubMed ID: 35736347
[TBL] [Abstract][Full Text] [Related]
4. Cardiac morbidity & mortality in patients with breast cancer: A review.
Dhir AA; Sawant SP
Indian J Med Res; 2021 Aug; 154(2):199-209. PubMed ID: 35295010
[TBL] [Abstract][Full Text] [Related]
5. Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials.
Rygiel K
Indian J Pharmacol; 2016; 48(5):490-497. PubMed ID: 27721532
[TBL] [Abstract][Full Text] [Related]
6. Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies : Position paper of the Heart Failure Working Group of the Austrian Society of Cardiology.
Bergler-Klein J; Rainer PP; Wallner M; Zaruba MM; Dörler J; Böhmer A; Buchacher T; Frey M; Adlbrecht C; Bartsch R; Gyöngyösi M; Fürst UM
Wien Klin Wochenschr; 2022 Sep; 134(17-18):654-674. PubMed ID: 35507087
[TBL] [Abstract][Full Text] [Related]
7. Microtubule Inhibitors and Cardiotoxicity.
Joshi AM; Prousi GS; Bianco C; Malla M; Guha A; Shah M; Brown SA; Patel B
Curr Oncol Rep; 2021 Feb; 23(3):30. PubMed ID: 33582937
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer treatment-induced cardiotoxicity.
Martel S; Maurer C; Lambertini M; Pondé N; De Azambuja E
Expert Opin Drug Saf; 2017 Sep; 16(9):1021-1038. PubMed ID: 28697311
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial to evaluate the impact of exercise-based cardiac rehabilitation for the prevention of chemotherapy-induced cardiotoxicity in patients with breast cancer: ONCORE study protocol.
Díaz-Balboa E; González-Salvado V; Rodríguez-Romero B; Martínez-Monzonís A; Pedreira-Pérez M; Palacios-Ozores P; López-López R; Peña-Gil C; González-Juanatey JR
BMC Cardiovasc Disord; 2021 Apr; 21(1):165. PubMed ID: 33827450
[TBL] [Abstract][Full Text] [Related]
10. HER2+ breast cancer treatment and cardiotoxicity: monitoring and management.
Jerusalem G; Lancellotti P; Kim SB
Breast Cancer Res Treat; 2019 Sep; 177(2):237-250. PubMed ID: 31165940
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer.
Dent SF; Morse A; Burnette S; Guha A; Moore H
Curr Oncol Rep; 2021 Aug; 23(11):128. PubMed ID: 34453232
[TBL] [Abstract][Full Text] [Related]
12. Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities.
Guha A; Armanious M; Fradley MG
Trends Cardiovasc Med; 2019 Jan; 29(1):29-39. PubMed ID: 29910109
[TBL] [Abstract][Full Text] [Related]
13. SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function.
Lynce F; Barac A; Tan MT; Asch FM; Smith KL; Dang C; Isaacs C; Swain SM
Oncologist; 2017 May; 22(5):518-525. PubMed ID: 28314836
[TBL] [Abstract][Full Text] [Related]
14. Heart Failure in Breast Cancer Survivors: Focus on Early Detection and Novel Biomarkers.
Chen D; Kelly C; Haw TJ; Lombard JM; Nordman IIC; Croft AJ; Ngo DTM; Sverdlov AL
Curr Heart Fail Rep; 2021 Dec; 18(6):362-377. PubMed ID: 34731413
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant breast cancer treatments cardiotoxicity and modern methods of detection and prevention of cardiac complications.
Bikiewicz A; Banach M; von Haehling S; Maciejewski M; Bielecka-Dabrowa A
ESC Heart Fail; 2021 Aug; 8(4):2397-2418. PubMed ID: 33955207
[TBL] [Abstract][Full Text] [Related]
16. Cardiac Complications in the Adult Bone Marrow Transplant Patient.
Tuzovic M; Mead M; Young PA; Schiller G; Yang EH
Curr Oncol Rep; 2019 Mar; 21(3):28. PubMed ID: 30826891
[TBL] [Abstract][Full Text] [Related]
17. Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer.
Curigliano G; de Azambuja E; Lenihan D; Calabrò MG; Cardinale D; Cipolla CM
Oncologist; 2019 Nov; 24(11):e1034-e1043. PubMed ID: 31064888
[TBL] [Abstract][Full Text] [Related]
18. Cardiac Toxicity from Breast Cancer Treatment: Can We Avoid This?
Caron J; Nohria A
Curr Oncol Rep; 2018 Jun; 20(8):61. PubMed ID: 29876677
[TBL] [Abstract][Full Text] [Related]
19. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.
Pudil R; Mueller C; Čelutkienė J; Henriksen PA; Lenihan D; Dent S; Barac A; Stanway S; Moslehi J; Suter TM; Ky B; Štěrba M; Cardinale D; Cohen-Solal A; Tocchetti CG; Farmakis D; Bergler-Klein J; Anker MS; Von Haehling S; Belenkov Y; Iakobishvili Z; Maack C; Ciardiello F; Ruschitzka F; Coats AJS; Seferovic P; Lainscak M; Piepoli MF; Chioncel O; Bax J; Hulot JS; Skouri H; Hägler-Laube ES; Asteggiano R; Fernandez TL; de Boer RA; Lyon AR
Eur J Heart Fail; 2020 Nov; 22(11):1966-1983. PubMed ID: 33006257
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies.
Dempsey N; Rosenthal A; Dabas N; Kropotova Y; Lippman M; Bishopric NH
Breast Cancer Res Treat; 2021 Jul; 188(1):21-36. PubMed ID: 34115243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
